Azienda Ospedale Maggiore Della Carita
Welcome,         Profile    Billing    Logout  
 16 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gaidano, Gianluca
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting
3
128
Europe
R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)
Fondazione Italiana Linfomi - ETS
Lymphoma, Follicular
01/23
08/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated
2
5
Europe
Rituximab, Chemotherapy, Tenofovir alafenamide
Gruppo Italiano Malattie EMatologiche dell'Adulto
Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia
05/24
05/24
SAKK 38/19, NCT04604067: Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Active, not recruiting
2
260
Europe
Acalabrutinib
Swiss Group for Clinical Cancer Research
Diffuse Large B-cell Lymphoma
10/25
12/30
MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting
2
28
Europe
Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet
Niguarda Hospital
CLL Transformation
09/26
12/26
KCP-330-009, NCT02227251 / 2014-001977-15: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Submitted NDA in South Korea for rrDLBCL
Jan 2021 - Jan 2021: Submitted NDA in South Korea for rrDLBCL
Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
Dec 2020 - Dec 2020: Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
More
Recruiting
2
244
Europe, Canada, US, RoW
Selinexor, KPT-330
Karyopharm Therapeutics Inc
Diffuse Large B-cell Lymphoma
04/27
11/27
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
02/27
02/27
ONCO-AGING, NCT04478916: Impact of the Comprehensive Geriatric Assessment on the Quality of Life OF Elderly Patients

Recruiting
N/A
144
Europe
Lorenza Scotti
Hematologic Malignancies, Solid Tumor, Elderly Patients
09/21
05/22
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting
N/A
148
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia, Pregnancy
12/22
12/22
GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

Recruiting
N/A
321
Europe
Venetoclax
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia
01/23
10/25
ITP0918, NCT03465020: Investigation on a Dynamic Cohort of Italian Patients With Active ITP

Recruiting
N/A
861
Europe
Observation
Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation
Idiopathic Thrombocytopenic Purpura
07/23
07/23
NCT04600804: The Role of 18F-FDG-PET for Staging and Prognostication

Active, not recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
10/23
01/25
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Recruiting
N/A
520
Europe
Quality of life questionnaires
Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myeloma
12/24
12/24
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Recruiting
N/A
300
Europe, US, RoW
International Extranodal Lymphoma Study Group (IELSG)
Nodal Marginal Zone Lymphoma
12/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gaidano, Gianluca
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting
3
128
Europe
R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)
Fondazione Italiana Linfomi - ETS
Lymphoma, Follicular
01/23
08/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated
2
5
Europe
Rituximab, Chemotherapy, Tenofovir alafenamide
Gruppo Italiano Malattie EMatologiche dell'Adulto
Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia
05/24
05/24
SAKK 38/19, NCT04604067: Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Active, not recruiting
2
260
Europe
Acalabrutinib
Swiss Group for Clinical Cancer Research
Diffuse Large B-cell Lymphoma
10/25
12/30
MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting
2
28
Europe
Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet
Niguarda Hospital
CLL Transformation
09/26
12/26
KCP-330-009, NCT02227251 / 2014-001977-15: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Submitted NDA in South Korea for rrDLBCL
Jan 2021 - Jan 2021: Submitted NDA in South Korea for rrDLBCL
Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
Dec 2020 - Dec 2020: Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
More
Recruiting
2
244
Europe, Canada, US, RoW
Selinexor, KPT-330
Karyopharm Therapeutics Inc
Diffuse Large B-cell Lymphoma
04/27
11/27
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
02/27
02/27
ONCO-AGING, NCT04478916: Impact of the Comprehensive Geriatric Assessment on the Quality of Life OF Elderly Patients

Recruiting
N/A
144
Europe
Lorenza Scotti
Hematologic Malignancies, Solid Tumor, Elderly Patients
09/21
05/22
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting
N/A
148
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia, Pregnancy
12/22
12/22
GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

Recruiting
N/A
321
Europe
Venetoclax
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia
01/23
10/25
ITP0918, NCT03465020: Investigation on a Dynamic Cohort of Italian Patients With Active ITP

Recruiting
N/A
861
Europe
Observation
Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation
Idiopathic Thrombocytopenic Purpura
07/23
07/23
NCT04600804: The Role of 18F-FDG-PET for Staging and Prognostication

Active, not recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
10/23
01/25
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Recruiting
N/A
520
Europe
Quality of life questionnaires
Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myeloma
12/24
12/24
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Recruiting
N/A
300
Europe, US, RoW
International Extranodal Lymphoma Study Group (IELSG)
Nodal Marginal Zone Lymphoma
12/26
12/26

Download Options